Funding Rounds · Series A

AELIX Therapeutics — Series A (estimated) · €1.86M

Aelix Therapeutics, which develops a therapeutic HIV vaccine, received €1.858M through a CDTI Innvierte co-investment: €880K from CDTI and €978K between Caixa Innvierte Start and Ysios BioFund II Innvierte. No stage or lead was stated. The HQ city is not in the article and comes from background knowledge.

Lead not disclosed RoundSeries A (estimated) Announced15 Sep 2021 CityBarcelona SectorHealthtech & Bio · Biotech Source

Something wrong? Suggest a correction →

The company

AELIX Therapeutics
aelixtherapeutics.com
Series A Barcelona

Investors 3

Caixa Innvierte Start (Criteria Caixa / Caixa Capital Risc)
www.caixacapitalrisc.es
Profile: Criteria Capital Risc
Spain
CDTI Innvierte
www.cdti.es
Profile: Centro para el Desarrollo Tecnológico y la Innovación
Spain
Ysios BioFund II Innvierte (Ysios Capital)
www.ysioscapital.com
Profile: Ysios Capital
Spain

← All funding rounds

Start typing to search across everything.
↑↓ navigate↵ openesc close? shortcuts
Keyboard shortcuts
/ Ctrl K
Search
j k
Next or previous row
↵
Open the row
Ctrl ↵
Open it in a new tab
[ ]
Previous or next page
?
This list